BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Pfizer launches Rimegepant in Singapore for Acute and Prophylactic Migraine relief

January 31, 2024 | News

NURTECÃ?Â®Ã?Â (rimegepant) is the first and only oral medicine approved for both acute and prophylactic treatmentÃ?Â of Episodic MigraineÃ?Â



Pfizer's NURTEC® (rimegepant), an orally disintegrating tablet for both the acute treatment of migraine is now available in Singapore. Adults who have at least four migraine attacks per month can use NURTEC® to treat episodic migraine with or without aura.

"We are pleased to introduce NURTEC® to Singapore, a treatment addressing both the immediate relief and preventive needs of migraine sufferers," said Deborah Seifert, Cluster Lead, Malaysia-Indonesia-Singapore-Philippines (MISP), Pfizer Emerging Markets Asia.

Results from the Phase 3 study published in *Lancet* demonstrated that a single dose of NURTEC® provided superior pain reduction and reductions in associated symptoms of migraine at two hours compared to placebo.

"Rimegepant represents a significant stride forward. By addressing both preventive needs and acute attack relief, including pain, with a single medication. This new class of medication, gepants, has the potential to redefine the standard of care and provide hope to those who have long felt underserved by existing migraine treatments" explains Professor Peter Goadsby, Professor of Neurology, King's College London.

Rimegepant is approved in over 40 markets to date, including in the United States, and in the European Union and the United Kingdom under the brand name VYDURA® ODT. Additional regulatory applications are under review around the world.